ImmuPharma (LON:IMM) Trading 39.7% Higher – Should You Buy?

ImmuPharma plc (LON:IMMGet Free Report) shares were up 39.7% during trading on Monday . The company traded as high as GBX 7.14 ($0.09) and last traded at GBX 5.50 ($0.07). Approximately 53,455,387 shares were traded during trading, an increase of 148% from the average daily volume of 21,559,516 shares. The stock had previously closed at GBX 3.94 ($0.05).

ImmuPharma Trading Down 15.6 %

The firm has a market cap of £20.74 million, a P/E ratio of -498.00 and a beta of 1.53. The company’s fifty day moving average price is GBX 1.98 and its two-hundred day moving average price is GBX 1.80.

About ImmuPharma

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Featured Stories

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.